Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours

Drugs

Volumn 75, Issue 9, 2015, Pages 1009-1017

  Shirley, Matt ^a   Keating, Gillian M ^a  

^a Adis ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; REGORAFENIB; SUNITINIB; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; ERYTHEMA MULTIFORME; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFECTION; JAPANESE (PEOPLE); LIVER TOXICITY; MACULOPAPULAR RASH; NECROSIS; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; STEVENS JOHNSON SYNDROME; VOLUME OF DISTRIBUTION; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84930930627     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0406-x     Document Type: Article

References (33)

1. Iorio N, Sawaya RA, Friedenberg FK. Review article: the biology, diagnosis and management of gastrointestinal stromal tumours. Aliment Pharmacol Ther. 2014;39(12):1376-86.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am. 2013;42(2):399-415.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline®): soft tissue sarcoma (Version 1.2015). 2015. http://www.nccn.org. Accessed 13 Apr 2015.
4. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):321-6.
5. Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am. 2013;27(5):905-20.
6. Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2014;6(3):115-27.
7. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56(1):1-9.
8. Siddiqui MAA, Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs. 2007;67(5):805-20.
9. Deeks ED, Keating GM. Sunitinib. Drugs. 2006;66(17):2255-66.
10. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38.
11. AY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009;15(22):6862-70.
12. US FDA. Stivarga (regorafenib): prescribing information. 2015. http://www.fda.gov. Accessed 20 Apr 2015.
13. European Medicines Agency. Stivarga: summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 30 Mar 2015.
14. Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302.
15. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-55.
16. Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135(6):1487-96.
17. Van Looy T, Gebreyohannes YK, Wozniak A, et al. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clin Sarcoma Res. 2014;4:10.
18. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013;12(7):1322-31.
19. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658-67.
20. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722-7.
21. European Medicines Agency. Stivarga: CHMP extension of indication variation assessment report. 2014. http://www.ema.europa.eu. Accessed 30 Mar 2015.
22. Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014;32(1):104-12.
23. Health Canada. Stivarga (regorafenib tablets): product monograph. 2015. http://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng. Accessed 30 Mar 2015.
24. George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30(19):2401-7.
25. Demetri GD, Reichardt P, Kang Y-K, et al. An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID) [abstract no. 110]. In: 2015 Gastrointestinal Cancers Symposium. 2015.
26. Komatsu Y, Doi T, Sawaki A, et al. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol. 2015. doi: 10.1007/s10147-015-0790-y.
27. Chang J, Casali PG, Reichardt P, et al. Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial [abstract no. 3830]. In: The European Cancer Congress. 2013.
28. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.
29. Hartmann JT, Haap M, Kopp H-G, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470-81.
30. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs. 2012;21(6):879-89.
31. Grothey A, George S, van Cutsem E, et al. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19(6):669-80.
32. Kang Y-K, Ryu M-H, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175-82.
33. Yip D, Zalcberg J, Ackland S, et al. Controversies in the management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol. 2014;10(3):216-27.